Table 2.

Most frequently reported adverse events^a and all reported serious adverse events (safety populations)

A. IDEAL study open‐label extension, switching from rivastigmine capsule to rivastigmine patch (n = 209)b
	n (%)
Any adverse event	30 (14.4%)
Nausea	5 (2.4%)
Vomiting	4 (1.9%)
Any serious adverse event	0
B. SWAP study, switching from donepezil tablets to rivastigmine patch
	n (%)
	Donepezil tablets to rivastigmine patch – immediate switch (n = 131)	Donepezil tablets to rivastigmine patch – delayed switch (n = 130)
Any adverse event	36 (27.5%)	45 (34.6%)
Nausea	5 (3.8%)	1 (0.8%)
Vomiting	1 (0.8%)	0
Decreased appetite	4 (3.1%)	0
Bradycardia	3 (2.3%)	0
Hallucination	3 (2.3%)	0
Constipation	0	6 (4.6%)
Application site reaction	1 (0.8%)	5 (3.8%)
Somnolence	2 (1.5%)	4 (3.1%)
Agitation	3 (2.3%)	3 (2.3%)
Any serious adverse event	4 (3.1%)	2 (1.5%)
Anemia	0	1 (0.8%)
Bradycardia	1 (0.8%)	0
Abscess limb	1 (0.8%)	0
Fall	0	1 (0.8%)
Hip fracture	0	1 (0.8%)
Dehydration	1 (0.8%)	0
Benign vaginal neoplasm	0	1 (0.8%)
Lethargy	1 (0.8%)	0
Mental status changes	1 (0.8%)	0
Dyspnea	0	1 (0.8%)

^aIn addition to nausea and vomiting, adverse events occurring in at least 2% of patients in any treatment group are reported.

^bAdverse and serious adverse events reported during the “switch” phase (weeks 1–4 of the open‐label extension).